Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Luspatercept

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Celgene Corp's Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US
    Celgene Corp's Reblozyl® (luspatercept-aamt) Receives Suppl Approval in US

    16 May 2024

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761136

    FDA
    16 May 2024
    Share Share
    Ahead of likely approval, ICER finds Geron’s imetelstat at $250,000 annually
    Ahead of likely approval, ICER finds Geron’s imetelstat at $250,000 annually

    09 May 2024

    // Lia DeGroot ENDPTS

    https://endpts.com/ahead-of-likely-approval-icer-finds-gerons-imetelstat-is-not-cost-effective-at-250000-annually/

    Lia DeGroot ENDPTS
    09 May 2024
    Share Share
    EC Expands Approval of BMS Reblozyl for LR-MDS
    EC Expands Approval of BMS Reblozyl for LR-MDS

    02 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240402231542/en

    BUSINESSWIRE
    02 Apr 2024
    Share Share
    EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes
    EC expands Reblozyl’s approval for treatment of myelodysplastic syndromes

    02 Apr 2024

    // INDIANPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/ec-expands-reblozyls-approval-for-treatment-of-myelodysplastic-syndromes-15475

    INDIANPHARMAPOST
    02 Apr 2024
    Share Share
    Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl
    Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl

    23 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240221131768/en

    BUSINESSWIRE
    23 Feb 2024
    Share Share
    BMS Presents Efficacy and Safety Analysis of the Phase 3 Trial of Reblozyl
    BMS Presents Efficacy and Safety Analysis of the Phase 3 Trial of Reblozyl

    09 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231208530578/en

    BUSINESSWIRE
    09 Dec 2023
    Share Share